Team:UC Davis/Project

From 2009.igem.org

(Difference between revisions)
 
(One intermediate revision not shown)
Line 66: Line 66:
style=""><big><big style="text-decoration: underline;"><span
style=""><big><big style="text-decoration: underline;"><span
style="font-weight: bold;">What is Celiac Disease?</span></big></big><o:p></o:p></span>
style="font-weight: bold;">What is Celiac Disease?</span></big></big><o:p></o:p></span>
-
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Celiac Disease is an autoimmune
+
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Celiac Disease is an
 +
autoimmune
disorder that occurs inside the small
disorder that occurs inside the small
-
intestine. When the body cannot properly digest gliadin (a component of gluten),
+
intestine. When the body cannot properly digest gliadin (a component of
 +
gluten),
this leads to an immune response on the surface of the small intestine
this leads to an immune response on the surface of the small intestine
(14).
(14).
Different people have varying degrees of immune
Different people have varying degrees of immune
response
response
-
such as bloating, diarrhea, and weight loss (14). An estimated one out of 133 Americans currently suffer from this
+
such as bloating, diarrhea, and weight loss (14). An estimated one out
-
disease (11). Considering the estimated 3.08 million people in America, this isn't a minor issue. In fact, it was one of our teammate's friends suffering from celiac who initially sparked our interest in designing this project. <o:p></o:p><span style=""><small><span
+
of 133 Americans currently suffer from this
 +
disease (11). Considering the estimated 3.08 million people in America,
 +
this isn't a minor issue. In fact, it was one of our teammate's friends
 +
suffering from celiac who initially sparked our interest in designing
 +
this project. <o:p></o:p><span style=""><small><span
style="font-style: italic;"><br>
style="font-style: italic;"><br>
</span></small></span></p>
</span></small></span></p>
Line 82: Line 88:
style="font-weight: bold;"></span><br>
style="font-weight: bold;"></span><br>
&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; <br>
&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; <br>
-
&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; The inside surface of the small intestine is covered with small microvilli, constituting the brush border membrane. In the normal small intestine, the brush border membrane is where polysaccharides, proteins, and fat droplets are digested into smaller parts that then get absorbed into the bloodstream. <br>
+
&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; The inside surface of the small
 +
intestine is covered with small microvilli, constituting the brush
 +
border membrane. In the normal small intestine, the brush border
 +
membrane is where polysaccharides, proteins, and fat droplets are
 +
digested into smaller parts that then get absorbed into the
 +
bloodstream. <br>
</p>
</p>
<p><o:p></o:p><span style=""><big><span
<p><o:p></o:p><span style=""><big><span
-
style="font-weight: bold; font-style: italic;">What happens in the small intestine of people with celiac
+
style="font-weight: bold; font-style: italic;">What happens in the
 +
small intestine of people with celiac
disease?</span></big><o:p></o:p></span></p>
disease?</span></big><o:p></o:p></span></p>
<span style="font-weight: bold;"></span>
<span style="font-weight: bold;"></span>
-
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; The brush border characteristic to people with celiac disease allows large molecules such as gliadin to go straight
+
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; The brush border
 +
characteristic to people with celiac disease allows large molecules
 +
such as gliadin to go straight
into the
into the
blood stream without directing them through the transcellular route.
blood stream without directing them through the transcellular route.
Line 94: Line 108:
gliadin passes through, Antigen Presenting Cells (APCs) recognize
gliadin passes through, Antigen Presenting Cells (APCs) recognize
gliadin as a
gliadin as a
-
foreign object and attack. This immune response results in the inflammation of
+
foreign object and attack. This immune response results in the
 +
inflammation of
the surface of the intestine with loss of the normal cells required for
the surface of the intestine with loss of the normal cells required for
absorption of sugars, protein, and fat from the diet. <o:p></o:p></p>
absorption of sugars, protein, and fat from the diet. <o:p></o:p></p>
-
<p>In addition to the array of symtpoms illustrated above, the immune response may also damage intestinal villi, which are important
+
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; In addition to the array of
 +
symptoms illustrated above, the immune response may also damage
 +
intestinal villi, which are important
for
for
absorbing nutrients. The destruction of villi eventually leads to a
absorbing nutrients. The destruction of villi eventually leads to a
Line 105: Line 122:
people affected with this disorder can also suffer from autoimmune
people affected with this disorder can also suffer from autoimmune
thyroid
thyroid
-
disease, autoimmune liver disease, and rheumatoid arthritis (<i>diseases
+
disease, autoimmune liver disease, and rheumatoid arthritis (diseases
in
in
-
which body immune system attacks healthy cells/tissues</i>) (14). <o:p></o:p></p>
+
which body immune system attacks healthy cells/tissues) (14). <o:p></o:p></p>
<hr style="width: 100%; height: 2px;">
<hr style="width: 100%; height: 2px;">
<p><u><span
<p><u><span
Line 128: Line 145:
as a potential therapeutic approach."(8) However, enzymes studied
as a potential therapeutic approach."(8) However, enzymes studied
earlier
earlier
-
were not able to degrade gluten inside the stomach (before it reaches the small
+
were not able to degrade gluten inside the stomach (before it reaches
 +
the small
intestine), because they were "irreversibly inactivated by pepsin and
intestine), because they were "irreversibly inactivated by pepsin and
acidic pH, both present in the stomach."(8) <o:p></o:p></p>
acidic pH, both present in the stomach."(8) <o:p></o:p></p>
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Nevertheless, over the past
<p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Nevertheless, over the past
-
years, researchers have discovered an enzyme--a newly-identified prolyl endoprotease--from <i>Aspergillus niger</i>,  
+
years, researchers have discovered an enzyme--a newly-identified prolyl
-
that was
+
endoprotease--from <i>Aspergillus niger</i>, that was
observed to "work optimally at 4-5pH and remains stable at 2pH"(8).
observed to "work optimally at 4-5pH and remains stable at 2pH"(8).
Perhaps this enzyme will lead us to an alternative treatment for this
Perhaps this enzyme will lead us to an alternative treatment for this
-
disorder(8). Studies have shown that prolyl endoprotease from <i>A.niger</i> is able to "degrade gluten in vitro and under conditions
+
disorder(8). Studies have shown that prolyl endoprotease from <i>A.niger</i>
 +
is able to "degrade gluten in vitro and under conditions
similar
similar
-
to the ones present in the gastrointestinal tract." (8)&nbsp;; However, due
+
to the ones present in the gastrointestinal tract." (8)&nbsp;; However,
 +
due
to
to
licensing restrictions, we have opted not to work with this protein. <o:p></o:p></p>
licensing restrictions, we have opted not to work with this protein. <o:p></o:p></p>
Line 148: Line 168:
capsulata</span>) with gastric
capsulata</span>) with gastric
activity and
activity and
-
complementary substrate specificity(12). Using this method, there is a possibility of
+
complementary substrate specificity(12). Using this method, there is a
 +
possibility of
increasing the
increasing the
safe threshold of ingested gluten(12). One of the advantages of this
safe threshold of ingested gluten(12). One of the advantages of this
Line 181: Line 202:
<p class="MsoNormal"><span style="font-weight: bold;">Our project is
<p class="MsoNormal"><span style="font-weight: bold;">Our project is
split into two parts:</span><br>
split into two parts:</span><br>
-
1.Induced Secretion<br>
+
1. Induced Secretion<br>
</p>
</p>
<ul>
<ul>
Line 194: Line 215:
for measuring protein localization and activity</a></li>
for measuring protein localization and activity</a></li>
</ul>
</ul>
-
<a
 
-
href="https://2009.igem.org/Team:UC_Davis/assay_for_measuring_protein_localization_and_activity"></a>
 
<ul>
<ul>
</ul>
</ul>

Latest revision as of 02:30, 22 October 2009

lol

   
Project:
Celiac Disease          Current treatment           Our Approach
What is Celiac Disease?

        Celiac Disease is an autoimmune disorder that occurs inside the small intestine. When the body cannot properly digest gliadin (a component of gluten), this leads to an immune response on the surface of the small intestine (14). Different people have varying degrees of immune response such as bloating, diarrhea, and weight loss (14). An estimated one out of 133 Americans currently suffer from this disease (11). Considering the estimated 3.08 million people in America, this isn't a minor issue. In fact, it was one of our teammate's friends suffering from celiac who initially sparked our interest in designing this project.

What happens in the normal small intestine?
       
        The inside surface of the small intestine is covered with small microvilli, constituting the brush border membrane. In the normal small intestine, the brush border membrane is where polysaccharides, proteins, and fat droplets are digested into smaller parts that then get absorbed into the bloodstream.

What happens in the small intestine of people with celiac disease?

        The brush border characteristic to people with celiac disease allows large molecules such as gliadin to go straight into the blood stream without directing them through the transcellular route. Once gliadin passes through, Antigen Presenting Cells (APCs) recognize gliadin as a foreign object and attack. This immune response results in the inflammation of the surface of the intestine with loss of the normal cells required for absorption of sugars, protein, and fat from the diet.

        In addition to the array of symptoms illustrated above, the immune response may also damage intestinal villi, which are important for absorbing nutrients. The destruction of villi eventually leads to a lack of absorption of different nutrients, which can lead to malnutrition (14). Some people affected with this disorder can also suffer from autoimmune thyroid disease, autoimmune liver disease, and rheumatoid arthritis (diseases in which body immune system attacks healthy cells/tissues) (14).


Current treatments:

        Currently, no cure has been found for this illness. The only way to avoid the symptoms of celiac disease is by adopting a gluten-free diet (14, 12, and 11). However, you are highly likely to find gluten in your everyday diet (in foods such as grains), and people with celiac disease must purchase gluten-free substances from specialized grocery stores. "Oral supplementation with prolyl oligopeptidases that can digest and detoxify gluten has therefore been proposed as a potential therapeutic approach."(8) However, enzymes studied earlier were not able to degrade gluten inside the stomach (before it reaches the small intestine), because they were "irreversibly inactivated by pepsin and acidic pH, both present in the stomach."(8)

        Nevertheless, over the past years, researchers have discovered an enzyme--a newly-identified prolyl endoprotease--from Aspergillus niger, that was observed to "work optimally at 4-5pH and remains stable at 2pH"(8). Perhaps this enzyme will lead us to an alternative treatment for this disorder(8). Studies have shown that prolyl endoprotease from A.niger is able to "degrade gluten in vitro and under conditions similar to the ones present in the gastrointestinal tract." (8) ; However, due to licensing restrictions, we have opted not to work with this protein.

        Recently (year 2007), a study has suggested an alternative approach by combining a glutamine-specific endoprotease (EP-B2 from barley) and a prolyl endopeptidase (SC PEP from Sphingomonas capsulata) with gastric activity and complementary substrate specificity(12). Using this method, there is a possibility of increasing the safe threshold of ingested gluten(12). One of the advantages of this “combination product is that both enzymes are active and stable in stomach and can therefore be administered as lyophilized powders or simple capsules or tablets”(12).


Our approach:

        Gliadin induces an immune system response when it is absorbed into the blood stream through the small intestine. We plan to take advantage of this by breaking down gliadin in the stomach before it reaches the small intestine. We have developed a secretion system to release an enzyme that can break down gliadin. Also, in order to prevent our delivery system from taking residence anywhere outside of the stomach, we plan to incorporate the difference in pH between the stomach and small intestine with a pH-inducible apoptosis system. By adopting these two systems, we will create a pH-moderated secretion system.
        Unlike other suggested treatments requiring the consumption of capsules or tablets, our method of using E. coli as our delivery system is more cost- and time-efficient.


Our project is split into two parts:
1. Induced Secretion

2. Sensing pH  and inducing cell death